vs
Side-by-side financial comparison of Adaptive Biotechnologies Corp (ADPT) and TSS, Inc. (TSSI). Click either name above to swap in a different company.
Adaptive Biotechnologies Corp is the larger business by last-quarter revenue ($70.9M vs $60.9M, roughly 1.2× TSS, Inc.). TSS, Inc. runs the higher net margin — 20.0% vs 4.7%, a 15.2% gap on every dollar of revenue. On growth, Adaptive Biotechnologies Corp posted the faster year-over-year revenue change (35.1% vs 21.8%). Over the past eight quarters, TSS, Inc.'s revenue compounded faster (95.8% CAGR vs 28.1%).
ExpreS2ion Biotechnologies is a Danish biotechnology company specialised in the development of new vaccines and immunotherapy products based in Hørsholm, Denmark and listed on the Nasdaq First North Growth Market Sweden.
ADPT vs TSSI — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $70.9M | $60.9M |
| Net Profit | $3.4M | $12.2M |
| Gross Margin | 73.6% | 17.6% |
| Operating Margin | -27.1% | 1.5% |
| Net Margin | 4.7% | 20.0% |
| Revenue YoY | 35.1% | 21.8% |
| Net Profit YoY | — | 535.7% |
| EPS (diluted) | — | $0.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $70.9M | — | ||
| Q4 25 | $71.7M | $60.9M | ||
| Q3 25 | $94.0M | $41.9M | ||
| Q2 25 | $58.9M | $44.0M | ||
| Q1 25 | $52.4M | $99.0M | ||
| Q4 24 | $47.5M | $50.0M | ||
| Q3 24 | $46.4M | $70.1M | ||
| Q2 24 | $43.2M | $12.2M |
| Q1 26 | $3.4M | — | ||
| Q4 25 | $-13.6M | $12.2M | ||
| Q3 25 | $9.5M | $-1.5M | ||
| Q2 25 | $-25.6M | $1.5M | ||
| Q1 25 | $-29.9M | $3.0M | ||
| Q4 24 | $-33.7M | $1.9M | ||
| Q3 24 | $-32.1M | $2.6M | ||
| Q2 24 | $-46.2M | $1.4M |
| Q1 26 | 73.6% | — | ||
| Q4 25 | 74.6% | 17.6% | ||
| Q3 25 | 80.7% | 11.1% | ||
| Q2 25 | 69.4% | 17.8% | ||
| Q1 25 | 67.6% | 9.3% | ||
| Q4 24 | 62.0% | 14.4% | ||
| Q3 24 | 64.1% | 11.3% | ||
| Q2 24 | 55.3% | 37.3% |
| Q1 26 | -27.1% | — | ||
| Q4 25 | -17.8% | 1.5% | ||
| Q3 25 | 10.9% | -2.2% | ||
| Q2 25 | -42.5% | 5.1% | ||
| Q1 25 | -56.4% | 4.2% | ||
| Q4 24 | -71.3% | 0.0% | ||
| Q3 24 | -70.3% | 5.4% | ||
| Q2 24 | -109.6% | 14.0% |
| Q1 26 | 4.7% | — | ||
| Q4 25 | -18.9% | 20.0% | ||
| Q3 25 | 10.2% | -3.6% | ||
| Q2 25 | -43.5% | 3.4% | ||
| Q1 25 | -56.9% | 3.0% | ||
| Q4 24 | -71.0% | 3.8% | ||
| Q3 24 | -69.1% | 3.8% | ||
| Q2 24 | -107.0% | 11.5% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.08 | $0.44 | ||
| Q3 25 | $0.06 | $-0.06 | ||
| Q2 25 | $-0.17 | $0.06 | ||
| Q1 25 | $-0.20 | $0.12 | ||
| Q4 24 | $-0.22 | $0.08 | ||
| Q3 24 | $-0.22 | $0.10 | ||
| Q2 24 | $-0.31 | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $77.6M | $85.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $76.6M |
| Total Assets | $505.9M | $184.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $77.6M | — | ||
| Q4 25 | $70.5M | $85.5M | ||
| Q3 25 | $55.0M | $70.7M | ||
| Q2 25 | $43.2M | — | ||
| Q1 25 | $50.6M | — | ||
| Q4 24 | $47.9M | $23.2M | ||
| Q3 24 | $38.1M | $46.4M | ||
| Q2 24 | $59.8M | $8.3M |
| Q1 26 | — | — | ||
| Q4 25 | $218.8M | $76.6M | ||
| Q3 25 | $204.4M | $63.4M | ||
| Q2 25 | $179.7M | $9.5M | ||
| Q1 25 | $190.4M | $9.4M | ||
| Q4 24 | $202.7M | $7.1M | ||
| Q3 24 | $223.8M | $7.7M | ||
| Q2 24 | $241.6M | $5.2M |
| Q1 26 | $505.9M | — | ||
| Q4 25 | $512.7M | $184.9M | ||
| Q3 25 | $490.6M | $165.4M | ||
| Q2 25 | $496.6M | $139.5M | ||
| Q1 25 | $510.9M | $113.5M | ||
| Q4 24 | $539.4M | $96.6M | ||
| Q3 24 | $558.5M | $67.3M | ||
| Q2 24 | $584.9M | $28.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $16.3M |
| Free Cash FlowOCF − Capex | — | $15.8M |
| FCF MarginFCF / Revenue | — | 25.9% |
| Capex IntensityCapex / Revenue | — | 0.9% |
| Cash ConversionOCF / Net Profit | — | 1.34× |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $2.1M | $16.3M | ||
| Q3 25 | $-7.1M | $-18.4M | ||
| Q2 25 | $-12.4M | $16.3M | ||
| Q1 25 | $-28.5M | $20.6M | ||
| Q4 24 | $-12.5M | $-21.6M | ||
| Q3 24 | $-27.1M | $38.6M | ||
| Q2 24 | $-17.3M | $-4.3M |
| Q1 26 | — | — | ||
| Q4 25 | $1.4M | $15.8M | ||
| Q3 25 | $-7.5M | $-24.9M | ||
| Q2 25 | $-13.1M | $5.4M | ||
| Q1 25 | $-29.7M | $5.8M | ||
| Q4 24 | $-12.6M | $-28.4M | ||
| Q3 24 | $-27.4M | $38.6M | ||
| Q2 24 | $-19.0M | $-6.0M |
| Q1 26 | — | — | ||
| Q4 25 | 2.0% | 25.9% | ||
| Q3 25 | -8.0% | -59.3% | ||
| Q2 25 | -22.2% | 12.3% | ||
| Q1 25 | -56.7% | 5.8% | ||
| Q4 24 | -26.5% | -56.7% | ||
| Q3 24 | -59.0% | 55.1% | ||
| Q2 24 | -44.1% | -49.4% |
| Q1 26 | — | — | ||
| Q4 25 | 0.9% | 0.9% | ||
| Q3 25 | 0.4% | 15.3% | ||
| Q2 25 | 1.1% | 24.8% | ||
| Q1 25 | 2.4% | 15.0% | ||
| Q4 24 | 0.2% | 13.4% | ||
| Q3 24 | 0.7% | 0.1% | ||
| Q2 24 | 4.0% | 13.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.34× | ||
| Q3 25 | -0.75× | — | ||
| Q2 25 | — | 11.02× | ||
| Q1 25 | — | 6.93× | ||
| Q4 24 | — | -11.32× | ||
| Q3 24 | — | 14.60× | ||
| Q2 24 | — | -3.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADPT
Segment breakdown not available.
TSSI
| Procurement Revenues Segment | $43.2M | 71% |
| System Integration Services Segment | $14.2M | 23% |
| Facilities Segment | $3.5M | 6% |
